FDA grants Erasca fast track designation for ERAS-0015 in metastatic pancreatic cancer
ERAS•FDA grants Fast Track designation for ERAS-0015
Erasca won FDA Fast Track designation for ERAS-0015 to treat metastatic pancreatic adenocarcinoma.
The program is supported by Phase 1 data showing 57% uORR at 8 weeks in 2L+ KRAS G12X pancreatic cancer.
The company plans a Phase 3 pancreatic trial. Two potentially pivotal lung cancer studies are also planned.
